Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • IL-12: Bad news for the heart?
  • Therapeutic lymphangiogenesis.
  • ICOS, IL-17, and arthritis.
  • CD44 and tuberculosis resistance.
  • Mitochondrial mechanotransmission.
  • Version history
  • Article usage
  • Citations to this article

Advertisement

In this issue Free access | 10.1172/JCI119969

In This Issue

Published March 1, 2003 - More info

Published in Volume 111, Issue 5 on March 1, 2003
J Clin Invest. 2003;111(5):563–563. https://doi.org/10.1172/JCI119969.
© 2003 The American Society for Clinical Investigation
Published March 1, 2003 - Version history
View PDF
IL-12: Bad news for the heart?

Myocarditis is associated with viral infections. In addition, several lines of evidence suggest that autoreactive CD8+ T cells play a role in the disease. As IL-12 is part of the innate immune response to viral infections and has been implicated in autoimmune diseases, including myocarditis, Andrew Lichtman and colleagues investigated how IL-12 contributes to the differentiation of T cells that damage the heart. The researchers used a new mouse model of myocarditis that allowed the comparison of different populations of cytotoxic CD8+ T cells specific for the same defined myocardial antigen. Their results (pages 671–680) showed that while IL-12 was not essential for the generation of cytolytic IFN-γ-producing effector T cells, only CD8+ T cells primed in the presence of IL-12 were able to proliferate in vivo and infiltrate the heart in significant numbers. IL-12 thus seems to play an important role in the differentiation of the pathogenic CD8+ T cells that underlie the autoimmune component of myocarditis.

Therapeutic lymphangiogenesis.

Mutations in VEGFR-3 cause hereditary lymphedema. While this is a rare disorder, secondary lymphedema, caused by surgical removal of lymph nodes, radiation therapy, or infectious diseases, is a common and disabling condition. Various lines of evidence suggest the potential of the VEGFR-3 ligand VEGF-C for the treatment of lymphedema. Working in two animal models of acute secondary lymphedema, Douglas Losordo and colleagues report (pages 717–725) that local transfer of naked plasmid DNA encoding human VEGF-C promoted lymphangiogenesis and improved physical, functional, and pathologic aspects of the disease in rabbits and mice. Their results also suggest that while plasmid transfer induces only transient expression of VEGF-C, once the lymphatic connection is re-established, drainage function can be maintained.

ICOS, IL-17, and arthritis.

ICOS is a costimulator expressed on activated T cells and involved in Th2 function and class switching by B cells. Having previously shown that lack of ICOS enhances the susceptibility in mice to experimental autoimmune encephalomyelitis, Chen Dong and colleagues subsequently examined whether ICOS has a role in rheumatoid arthritis. Working with a well-established mouse model of arthritis, they report (pages 701–706) that in the absence of ICOS, mice normally susceptible to collagen-induced arthritis were completely protected against the disease. ICOS-knockout mice had reduced levels of anti-collagen IgM and IgG antibodies as well as lower levels of IL-17, a proinflammatory cytokine implicated in rheumatoid arthritis. These results warrant additional investigation into the potential of ICOS as a therapeutic target in rheumatoid arthritis.

CD44 and tuberculosis resistance.

CD44 is an adhesion molecule involved in inflammatory processes. It is present on hematopoietic cells and linked to the cytoskeleton. As cell migration and phagocytosis are dependent on cytoskeletal rearrangements and important in the immune response against Mycobacterium tuberculosis, Jaklien Leemans and colleagues investigated the role of CD44 in pulmonary tuberculosis. Their results (pages 681–689) suggest that CD44 expressed on macrophages is involved in the binding and subsequent uptake of M. tuberculosis. Mice lacking CD44 exhibited a more severe pathological response to infection with M. tuberculosis: they had a profound defect in the early recruitment of macrophages to the lungs, enhanced mycobacterial outgrowth in lung and liver, and a reduced rate of survival compared with controls. CD44 is a unique molecule implicated in the clearance of mycobacteria.

Mitochondrial mechanotransmission.

Endothelial cells in the lung generate a proinflammatory response to even modest elevations of vascular pressure. This involves expression of the leukocyte adhesion receptor P-selectin on endothelial cells, which increases leukocyte rolling on the vessel surface. Interested in the underlying mechanisms, Jahar Bhattacharya and colleagues applied real-time, in situ fluorescence microscopy in lung capillaries. As they report (pages 691–699), pressure elevation increased the amplitude of cytosolic Ca2+ oscillations, which in turn increased the amplitude of mitochondrial Ca2+ oscillations and the production of reactive oxygen species. P-selectin expression could be inhibited by antioxidants and inhibitors of mitochondrial metabolism, demonstrating that mitochondria are the organelles that couple the mechanical effects of higher pressure to the capillary’s proinflammatory response.

Version history
  • Version 1 (March 1, 2003): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • IL-12: Bad news for the heart?
  • Therapeutic lymphangiogenesis.
  • ICOS, IL-17, and arthritis.
  • CD44 and tuberculosis resistance.
  • Mitochondrial mechanotransmission.
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts